v3.10.0.1

Statement of Financial Position - USD ($)	Mar. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash	$ 105	$ 82
Total Current Assets	105	82
TOTAL ASSETS	105	82
CURRENT LIABILITIES
Accounts payable and accrued expenses	493,347	451,838
Accounts payable - related party	92,007	92,007
Note payable - related party	6,003	2,536
Notes Payable	66,500	49,000
Convertible notes payable (net of discount)	473,984	408,630
Derivative Liability	4,792,940	792,898
Total Current Liabilities	5,924,781	1,796,909
Total Liabilities	5,924,781	1,796,909
Commitments and Contingencies	0	0
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock; $0.0001 par value, 20,000,000 shares authorized, 3,714,000 and 3,554,000 issued or outstanding respectively, as of March 31, 2018 and December 31, 2017 respectively,	372	356
Common stock; $0.0001 par value, 980,000,000 shares authorized, 44,140,257 and 32,303,283 issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	4,415	3,231
Additional paid-in capital	12,723,262	12,659,977
Accumulated deficit	(18,652,725)	(14,460,391)
Total Stockholders' Equity (Deficit)	(5,924,676)	(1,796,827)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 105	$ 82

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

MJ BIOTECH, INC. 10-Q